T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients

Eur J Intern Med. 2022 May:99:104-105. doi: 10.1016/j.ejim.2022.01.030. Epub 2022 Jan 24.

Affiliations

¹ Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon 21000, France.
² Department of Virology, Dijon University Hospital, Dijon, France.
³ Laboratory of Hematology, Dijon University Hospital, Bourgogne-Franche Comté, Dijon, France.
⁴ Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon 21000, France. Electronic address: bernard.bonnotte@chu-dijon.fr.

No abstract available

Keywords: Rituximab; SARS Cov2 vaccine; T-cells.

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19*
Humans
RNA, Viral
Rituximab / therapeutic use
SARS-CoV-2
T-Lymphocytes
Viral Vaccines*

Substances

RNA, Viral
Viral Vaccines
Rituximab
BNT162 Vaccine